Immunology and efficacy of MF59-adjuvanted vaccines

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

(2018) Timo Vesikari et al.   Lancet Respiratory Medicine

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells

(2017) Rossella Cioncada et al.   PLoS One

Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine

(2016) Eun-Ju Ko et al.   JOURNAL OF IMMUNOLOGY

Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+T Cells

(2016) Eun-Ju Ko et al.   JOURNAL OF VIROLOGY

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

(2016) Monica Vaccari et al.   NATURE MEDICINE

Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood

(2016) Helder I. Nakaya et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

(2016) David I. Bernstein et al.   VACCINE

Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines

(2016) Ji Yun Noh et al.   Human Vaccines & Immunotherapeutics

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction

(2016) Natasha Dubois Cauwelaert et al.   PLoS One

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

(2016) Niels Peter H. Knudsen et al.   Scientific Reports

Safety of vaccination against influenza A (H1N1) during pregnancy in the Netherlands: results on pregnancy outcomes and infant's health: cross-sectional linkage study

(2015) N van der Maas et al.   BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

(2015) Beatris Mastelic Gavillet et al.   JOURNAL OF IMMUNOLOGY

A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy

(2015) Massimo Fabiani et al.   VACCINE

Influenza vaccination in children primed with MF59®-adjuvanted or non-adjuvanted seasonal influenza vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

(2015) Markus Knuf et al.   Human Vaccines & Immunotherapeutics

MF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, with a Critical Role for Effector CD4 T Cells at Low Antibody Titers

(2015) Elisabetta Monaci et al.   Frontiers in Immunology

Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant

(2014) Robert B. Belshe et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells

(2014) A. Seubert et al.   JOURNAL OF IMMUNOLOGY

A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination

(2014) Keith S Reisinger et al.   Human Vaccines & Immunotherapeutics

Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults

(2012) Paolo Palma et al.   BIOLOGICALS

The history of MF59®adjuvant: a phoenix that arose from the ashes

(2012) Derek T O’Hagan et al.   Expert Review of Vaccines

MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action

(2012) E. Caproni et al.   JOURNAL OF IMMUNOLOGY

Synchronization of Dendritic Cell Activation and Antigen Exposure Is Required for the Induction of Th1/Th17 Responses

(2012) A. T. Kamath et al.   JOURNAL OF IMMUNOLOGY

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

(2012) Tom M Wilkinson et al.   NATURE MEDICINE

Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants

(2012) Rachel P. J. Lai et al.   PLoS One

Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein

(2012) Antu K. Dey et al.   VACCINE

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine

(2012) Manmohan Singh et al.   Human Vaccines & Immunotherapeutics

MF59 adjuvant: the best insurance against influenza strain diversity

(2011) Derek T O’Hagan et al.   Expert Review of Vaccines

Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88

(2011) A. Seubert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59

(2011) A. H. Ellebedy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

(2011) Massimiliano Fabbiani et al.   VACCINE

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

(2011) Samuele Calabro et al.   VACCINE

Immune mechanisms of protection: can adjuvants rise to the challenge?

(2010) Amy S McKee et al.   BMC BIOLOGY

AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity

(2009) A. M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)

(2009) Barbara C. Baudner et al.   PHARMACEUTICAL RESEARCH

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment

(2008) George S. Hui et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults

(2008) David I. Bernstein et al.   JOURNAL OF INFECTIOUS DISEASES

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice

(2008) Andreas Wack et al.   VACCINE